Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2007

Interferon Alpha-2a Expressed in Eggs

  • Viragen along with its partners in the field of avian transgenics, Roslin Institute and Oxford Biomedica, report the the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the OVA™ system.

    According to Viragen, this is the third therapeutic protein expressed thus far in a series of proof-of-principle studies, which aim to develop the OVA system as a large-scale biomanufacturing alternative for  expressing many types of therapeutic proteins. Interferon alpha-2a is the active ingredient in Roche’s Roferon®-A, approved for the treatment of certain chronic infectious diseases and cancers.

    The team previously demonstrated that OVA can repeatedly target expression to the oviduct and incorporation in the egg, rather than being expressed throughout the bird. They also showed that the characteristic of protein drug expression is able to be passed to subsequent generations. This combination of features is essential for a viable and cost-competitive manufacturing system, notes vp and managing director of Viragen, Scotland, Karen Jervis.

    Viragen previously reported OVA-expression of a humanized Mab being developed for advanced malignant melanoma and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of MS, as Avonex® (Biogen Idec) and Rebif® (Serono).

    Viragen holds the worldwide exclusive license to commercialize Avian Transgenic Technology as granted by Roslin Institute.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »